Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 9/20 | 0.42 |
| ▸ | XIAP | P98170 | 8/20 | 0.41 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631841 | 1.00 | GLA (0.43) | GLABIRC2XIAPBIRC3ALDH1A1 | |
| SCHEMBL2115283 | 0.92 | XIAP (0.46) | BIRC2XIAPBIRC3 | |
| SCHEMBL2631838 | 0.92 | XIAP (0.46) | BIRC2XIAPBIRC3 | |
| SCHEMBL13049925 | 0.87 | GLA (0.42) | GLABIRC2XIAPBIRC3CYP3A4 | |
| SCHEMBL15312597 | 0.87 | GLA (0.42) | GLABIRC2XIAPBIRC3CYP3A4 | |
| SCHEMBL2117128 | 0.85 | XIAP (0.45) | BIRC2XIAPBIRC3 | |
| SCHEMBL2114710 | 0.85 | XIAP (0.45) | BIRC2XIAPBIRC3 | |
| SCHEMBL2632164 | 0.85 | XIAP (0.45) | BIRC2XIAPBIRC3 | |
| SCHEMBL15085692 | 0.85 | XIAP (0.45) | BIRC2XIAPBIRC3 | |
| SCHEMBL2632138 | 0.84 | CYP3A4 (0.40) | BIRC2XIAPBIRC3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | GLA 921/4885BIRC2 4/4885XIAP 1/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | GLA 921/4885BIRC2 4/4885XIAP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.